Taken together, the ADC experiments, demonstrating the anti-α10-SAP-induced cell death of GBM cells both in vitro and in vivo, further support the potential of integrin α10β1 as a novel therapeutic target in GBMs. Here, IGKV6D-21 is linked to glioblastoma.